Skip to content

FMT, the gut microbiome and atherosclerosis: what the evidence shows

Most heart attacks and strokes start the same way: fatty plaque slowly building up inside the artery walls. That process is atherosclerosis. Over the past decade, researchers have found that gut bacteria help make TMAO, a molecule linked to plaque and to heart attacks. So can changing your gut bacteria with fecal microbiota transplant (FMT) protect your arteries? Here is the honest answer, from Resplice Institute in Hyderabad and Mumbai.

Illustration of atherosclerotic plaque and the gut-microbe TMAO pathwayAn artery narrowed by fatty plaque above a pathway showing gut microbes turning dietary choline and carnitine into TMA, which the liver converts to TMAO.Plaque narrows the arteryTMAOTMARed meat, eggsGut microbesTrimethylamineLiverIn blood

Evidence level 1 of 5

Laboratory and animal research. See the studies

Can FMT treat atherosclerosis?

Not on current evidence. Gut bacteria clearly influence atherosclerosis in animal studies, and FMT reduced artery lesions in mice. But the only randomised human trial, in men with metabolic syndrome, found that a single FMT changed gut bacteria without lowering TMAO production or artery inflammation. FMT for atherosclerosis is experimental. Statins, blood-pressure control, diet and exercise remain the foundation of treatment.

Key points

  • Gut bacteria turn choline and carnitine from foods such as red meat and egg yolks into TMA, which the liver converts to TMAO.
  • People with the highest TMAO levels had about 2.5 times the risk of heart attack, stroke or death in a 4,007-patient study.
  • People on a vegan diet make almost no TMAO from carnitine, so diet strongly shapes this pathway.
  • Lowering TMAO has not yet been shown to prevent heart attacks or strokes.
  • Outside recognised indications, FMT for atherosclerosis belongs in ethics-approved research.

What is fecal microbiota transplant (FMT)?

Fecal microbiota transplant (FMT), also called faecal microbiota transplantation or a stool transplant, moves a complete community of gut bacteria from a carefully screened, healthy donor into a patient’s bowel. The aim is to rebuild a balanced gut microbiome. It is usually given by colonoscopy or enema; some research studies use capsules.

FMT is an established treatment for recurrent C. difficile infection, where gastroenterology guidelines recommend it for suitable adults.3 For atherosclerosis it is experimental: it has not been shown to help people.

FMT for atherosclerosis at a glance

StatusExperimental. No proven benefit in people.
Strongest human evidenceOne 20-person randomised pilot, which found no effect on TMAO or artery inflammation.1
What is provenHigher TMAO is linked to more heart attacks, strokes and deaths.2
Biggest uncertaintyWhether lowering TMAO, by any means, prevents heart events.
Standard careStatins and other prescribed medicines, blood pressure and sugar control, no smoking, diet and exercise.
Where FMT fitsOnly within ethics-approved research, or for a separate recognised indication.

How are gut bacteria linked to artery plaque?

When you eat foods rich in choline and L-carnitine, such as red meat and egg yolks, certain gut bacteria turn them into trimethylamine (TMA). Your liver then converts TMA into trimethylamine N-oxide (TMAO).

TMAO is a marker and a likely contributor, not the whole story. Cholesterol, blood pressure, diabetes, smoking and genetics remain the biggest drivers of atherosclerosis.

Cross-sections showing an artery narrowing as plaque builds upThree artery cross-sections: a healthy open artery, one with early plaque, and one with advanced plaque leaving only a small channel for blood.Healthy arteryEarly plaqueAdvanced narrowing
Plaque builds up inside the artery wall and gradually narrows the channel for blood.
  • TMAO and heart eventsIn 4,007 people having coronary angiography, those with the highest TMAO levels had about 2.5 times the risk of heart attack, stroke or death over three years compared with the lowest.2
  • Gut bacteria are essentialWhen gut bacteria were suppressed with antibiotics, TMAO production from dietary choline was markedly reduced, showing that it depends on the microbiome.2
  • Red meat and plaqueGut microbes convert L-carnitine from red meat into TMAO; in mice this sped up atherosclerosis, but not when gut bacteria were suppressed.4
  • Diet changes the picturePeople on a vegan diet produced almost no TMAO when given carnitine, suggesting diet shapes this pathway strongly.1

How common is heart disease in India?

Cardiovascular diseases caused 28.1% of all deaths in India in 2016, up from 15.2% in 1990, and more than half of those deaths were in people younger than 70.5 Atherosclerosis sits behind most heart attacks and strokes, which is why new ways to understand and lower risk matter.

Share of all deaths in India caused by cardiovascular disease, 1990 and 2016Bar chart: cardiovascular disease caused 15.2% of deaths in India in 1990 and 28.1% in 2016.19901990: 15.2% of deaths in India were cardiovascular15.2%20162016: 28.1% of deaths in India were cardiovascular28.1%
Share of all deaths in India from cardiovascular disease. Global Burden of Disease Study.5
28.1%
of all deaths in India in 2016 were cardiovascular5
15.2%
was the share in 19905
53%
of cardiovascular deaths were in people under 705

What does the research say about FMT for atherosclerosis?

For atherosclerosis, the evidence for FMT sits at the bottom of our five-step ladder. The mechanism is well studied; proof of benefit in people is not there yet.

  1. 5Guideline-recommended careRecurrent C. difficile
  2. 4Multiple randomised trials and meta-analyses
  3. 3Small randomised trials
  4. 2Case reports and small studies
  5. 1Laboratory and animal researchAtherosclerosis evidence is here

Level 5 shows where fully proven FMT sits today, for comparison.

Level 5

Guideline-recommended care

FMT is a guideline-recommended treatment for recurrent C. difficile infection

The American Gastroenterological Association’s 2024 guideline recommends fecal microbiota-based therapy to prevent recurrent C. difficile infection in suitable adults. It is shown here as the reference point: this is what fully proven FMT looks like.3

  • Clinical guideline
  • Reference point
Level 4

Multiple randomised trials and meta-analyses

No meta-analyses of FMT for atherosclerosis exist.

Level 3

Small randomised trials

A single vegan-donor FMT changed gut bacteria but not TMAO or artery inflammation

Twenty men with metabolic syndrome were randomised to donor or their own stool. Two weeks later, TMAO production and aortic inflammation on PET-CT were unchanged.1

  • Randomised pilot trial
  • No benefit shown
Level 2

Case reports and small studies

No published human case reports show FMT reducing arterial plaque.

Level 1

Laboratory and animal research

Atherosclerosis risk could be transferred between mice through gut microbes

Mice given gut microbes from an atherosclerosis-prone strain developed more plaque on a choline-rich diet than mice given microbes from a resistant strain.6

  • Animal study
  • Mechanism shown

FMT from healthy mice reduced artery lesions in prone mice

Carotid artery lesions decreased in genetically prone (CTRP9-knockout) mice after FMT from healthy mice; the reverse transfer worsened them.7

  • Animal study
  • Benefit seen

Red-meat carnitine drives plaque through gut microbes in mice

Carnitine supplements increased TMAO and atherosclerosis in mice with intact gut bacteria but not when bacteria were suppressed.4

  • Animal study
  • Mechanism shown

What the researchers concluded

“Atherosclerosis susceptibility can be transmitted with gut microbial transplantation.”

Gregory et al., J Biol Chem, 2015 (mouse study)6

“…failed to elicit changes in TMAO production capacity or parameters related to vascular inflammation”

Smits et al., J Am Heart Assoc, 20181

Our reading of the evidence

The biology is compelling, but human proof is missing. TMAO is linked to heart events, yet lowering it has not been shown to prevent them. The one randomised FMT study in people used a single dose and measured results after only two weeks. Outside recognised indications, FMT for heart and artery disease should be used only within an ethics-committee-approved research study. For almost everyone, the priority is proven treatment plus diet and lifestyle change, which also reshapes the microbiome.

Research case studies

There are no published human case reports of FMT reducing arterial plaque. These are the two most relevant studies, summarised plainly. Neither involved Resplice patients.

Twenty men with metabolic syndrome given a vegan donor’s microbiota

Published case: Smits LP, J Am Heart Assoc, 2018

Participants
Twenty men with metabolic syndrome, randomised to a single FMT from a lean vegan donor or to their own stool as a placebo.
What was measured
How much TMAO each man produced from labelled choline and carnitine, and artery-wall inflammation on PET-CT scans of the abdominal aorta, at the start and two weeks later.
What changed
Their gut bacteria shifted, but TMAO production and markers of artery inflammation did not change.
What it tells us
One dose may not be enough. Diet, donor choice, repeat dosing and longer follow-up all need testing.

Mice genetically prone to atherosclerosis given healthy-mouse microbiota

Published case: Kim ES, Exp Mol Med, 2022

Model
CTRP9-knockout mice, which develop atherosclerosis readily, and healthy comparison mice.
What was done
FMT from healthy mice into prone mice, and the reverse transfer from prone mice into healthy ones.
What changed
Carotid artery lesions decreased in prone mice that received healthy microbiota. Healthy mice given the prone microbiota showed the opposite effect.
What it tells us
Gut microbes can influence plaque in animals. Many animal findings do not carry over to people.

Who might FMT be suitable for?

May be appropriate if

  • You have a recognised indication for FMT, such as recurrent C. difficile infection, regardless of your heart health
  • You are taking part in an ethics-committee-approved research study of FMT and cardiovascular disease
  • Your cardiologist is aware of and agrees with the plan
  • Microbiome testing is being used to guide diet changes, not as a substitute for proven heart treatment

Not advised if

  • FMT is never a substitute for statins, antiplatelet drugs, blood-pressure or diabetes treatment prescribed by your doctor
  • Chest pain, breathlessness, sudden weakness or slurred speech are emergencies: call 108 or 112, or go to the nearest hospital
  • Your immune system is severely weakened
  • You have recently had a heart attack, stroke or heart surgery and are not yet stable

What happens at a gut health assessment at Resplice?

Nobody is booked straight in for FMT. A typical pathway has five steps, and you can stop at any point. Your existing doctors are kept informed throughout.

  1. Initial assessment

    A cardiology-led review of your history, medicines, cholesterol, blood pressure, sugar levels and diet, plus any gut symptoms.

  2. Gut health evaluation

    Blood and stool tests look for infections, inflammation or other problems that need treating first, and help decide whether FMT is appropriate at all.

  3. Microbiome testing and treatment planning

    Microbiome testing shows which bacteria dominate your gut. Together with your cardiovascular risk profile, this shapes a written plan focused on proven risk reduction and diet.

  4. FMT procedure

    FMT is considered only where there is a recognised indication or an approved study. For most people the plan centres on diet, fibre and lifestyle instead.

  5. Follow-up and long-term monitoring

    We track lipids, blood pressure, glucose and gut health over time and coordinate with your cardiologist.

Is FMT safe? Side effects and donor screening

From donor to gut: how FMT works
  1. Healthy donor

    A healthy adult volunteer offers to donate.

  2. Screening

    Health questionnaire plus blood and stool tests.

  3. Stool bank

    Approved samples are processed and stored.

  4. Preparation

    Prepared under laboratory conditions.

  5. Delivery

    Given by colonoscopy, enema or another route.

  6. Engraftment

    Donor microbes settle and grow in the gut.

FMT is generally well tolerated when donors are carefully screened. The most common effects are short-lived bloating, cramps, loose stools or a mild fever. Rare but serious infections have been reported worldwide when donor screening was inadequate, which is why screening matters more than any other step.

People with severely weakened immune systems face higher risks, so your own health is reviewed in detail before FMT is considered, and the benefits, risks and alternatives are explained before you give written consent.

International donor-screening standards include

  • A detailed health, travel and lifestyle questionnaire for every donor
  • Blood tests for infections such as HIV, hepatitis and syphilis
  • Stool tests for C. difficile, disease-causing bacteria, parasites and drug-resistant organisms
  • Repeat testing over time, so that every batch can be traced from donor to patient

Resplice Institute’s FMT service in Hyderabad and Mumbai

Services

Clinical gut-health assessment, microbiome testing, FMT for recognised indications, post-treatment monitoring, and nutrition and lifestyle guidance.

Donor material

Supplied from Resplice Institute’s stool bank. Our donor-screening protocol is available on request.

Locations

Hyderabad (Manikonda and Patancheru, Telangana) and Mumbai, Maharashtra.

Charges

Fees depend on the tests and treatment plan, and are given to you in writing before any treatment.

Questions to ask before you consider FMT

Whether you come to us or go elsewhere, these are fair questions to put to any FMT provider. A good clinic will welcome them.

  • Why do you think FMT is appropriate for me, and what is the evidence for my condition?
  • Is this a recognised indication for FMT, or part of an ethics-committee-approved study?
  • How are donors screened, and can I see your screening protocol?
  • Which route will you use, how many sessions will I need, and how do I prepare?
  • Which side effects should I watch for, and who do I call if I feel unwell afterwards?
  • How will we measure whether it has helped, and when?
  • Should any of my current medicines change? (Never stop a medicine on your own.)
  • What is the total cost, including tests and follow-up visits?

Frequently asked questions about FMT for atherosclerosis

Can FMT remove plaque from arteries?

There is no evidence that FMT removes existing plaque in people. Mouse studies showed fewer lesions after FMT, but human trials have not confirmed any benefit.

What is TMAO?

TMAO (trimethylamine N-oxide) is made when gut bacteria break down choline and carnitine from food and the liver processes the result. Higher blood levels were linked to more heart attacks, strokes and deaths in a study of 4,007 patients.

Which foods raise TMAO?

Red meat (rich in L-carnitine) and choline-rich foods such as egg yolks are the main dietary sources. People eating plant-based diets tend to make far less TMAO.

Is FMT approved for heart disease?

No. FMT is guideline-recommended only for recurrent C. difficile infection. For atherosclerosis it remains experimental.

Can I take probiotics instead?

Probiotics contain a few strains, while FMT transfers a whole community. Neither has been proven to prevent heart attacks. Eating more fibre and less red meat is the best-supported way to shape your microbiome for heart health.

Do I need to stop my heart medicines?

No. Never stop statins, blood thinners or blood-pressure medicines without your cardiologist. Gut health care is meant to sit alongside them, never to replace them.

Who are stool donors and how are they screened?

Donors are healthy adult volunteers. Under international screening standards, each donor completes a detailed health questionnaire and passes blood and stool tests for infections and drug-resistant bacteria, with testing repeated over time. You are entitled to ask any FMT provider, including us, to explain their donor-screening protocol before treatment.

Where are Resplice Institute’s FMT centres?

Resplice Institute’s gut microbiome and FMT service is available in two cities: Hyderabad, at our Manikonda and Patancheru centres in Telangana, and Mumbai, Maharashtra. Assessments, microbiome testing and follow-up can be arranged in either city.

How much does FMT cost in Hyderabad and Mumbai?

Cost depends on the tests you need, the delivery route and the number of sessions in your plan. We give you a written estimate after the first consultation, before any treatment begins.

Contact and appointments

For an appointment, please bring your latest lipid profile, ECG or echo reports and a list of current medicines.

Appointment enquiries Call +91 80473 61350 Centres in Hyderabad and Mumbai

Our FMT centres

Hyderabad: Manikonda

Vaishnavione, 3rd Floor, above Vijetha Supermarket, Shivapuri Colony, Manikonda, Hyderabad, Telangana 500089

Hyderabad: Patancheru

RM/6 5-98, beside Rainbow Meadows, Krishna Reddy Pet, Patelguda, Patancheru, Telangana 502319

Mumbai

[Full clinic address and PIN code]
Mumbai, Maharashtra

References

  1. Smits LP, et al. Effect of vegan fecal microbiota transplantation on carnitine- and choline-derived trimethylamine-N-oxide production and vascular inflammation in patients with metabolic syndrome. J Am Heart Assoc. 2018;7(7):e008342. doi.org/10.1161/JAHA.117.008342
  2. Tang WHW, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013;368(17):1575–1584. doi.org/10.1056/NEJMoa1109400
  3. Peery AF, et al. AGA clinical practice guideline on fecal microbiota-based therapies for select gastrointestinal diseases. Gastroenterology. 2024;166(3):409–434. doi.org/10.1053/j.gastro.2024.01.008
  4. Koeth RA, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013;19(5):576–585. doi.org/10.1038/nm.3145
  5. India State-Level Disease Burden Initiative CVD Collaborators. The changing patterns of cardiovascular diseases and their risk factors in the states of India: the Global Burden of Disease Study 1990–2016. Lancet Glob Health. 2018. doi.org/10.1016/S2214-109X(18)30407-8
  6. Gregory JC, et al. Transmission of atherosclerosis susceptibility with gut microbial transplantation. J Biol Chem. 2015;290(9):5647–5660. doi.org/10.1074/jbc.M114.618249
  7. Kim ES, et al. Fecal microbiota transplantation ameliorates atherosclerosis in mice with C1q/TNF-related protein 9 genetic deficiency. Exp Mol Med. 2022. doi.org/10.1038/s12276-022-00728-w
Call Now Button